Women's health update: research news to ponder.
Breast cancer (Patient outcomes)
Cancer (Care and treatment)
Cancer (Patient outcomes)
Women (Health aspects)
|Publication:||Name: Townsend Letter Publisher: The Townsend Letter Group Audience: General; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 The Townsend Letter Group ISSN: 1940-5464|
|Issue:||Date: August-Sept, 2012 Source Issue: 349-350|
|Topic:||Event Code: 310 Science & research|
|Product:||Product Code: 8000432 Cancer Therapy NAICS Code: 621 Ambulatory Health Care Services|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Soy and Breast Cancer Prognosis: Continued Clarity
Data from the Women's Healthy Eating and Living (WHEL) were used to examine the effect of soy intake on breast cancer prognosis in 3088 breast cancer survivors. These women were early-stage breast cancer patients who were followed for an average of 7.3 years. Soy isoflavone intakes were measured after the diagnosis with a food frequency questionnaire. The association between soy intake and breast cancer recurrence and/or death was then tracked. As soy isoflavone intake increased, the risk of death decreased. Women at the highest levels of soy isoflavone intake (> 16.3 mg isoflavones/day) had a 54% reduction in risk of death.
Comment: This is the third epidemiologic study to report no adverse effects of soy foods on the prognosis of breast cancer. Soy foods, which contain isoflavones, a phytoestrogen, show both antiestrogenic and estrogenlike properties. The confusion and controversy have been that many studies have shown that isoflavones may protect against an initial breast cancer, but in a very few laboratory studies, certain isoflavone components of soy have been able to enhance the proliferation of breast cancer cells in select doses, and have been able to both promote and inhibit mammary tumor growth in rats.
However, in 2009, some clarity began to emerge for breast cancer patients. In survivors, one study in Asian women (the Shanghai Breast Cancer Survival Study) and another in US women (the Life after Cancer Epidemiology study) suggest that soy-containing foods do not negatively affect breast cancer prognosis, do not counteract the effect of the breast cancer drug tamoxifen, and may in fact provide potential benefits in decreasing risk of recurrence or death from breast cancer.
The current study has explored this issue further, by examining data from a randomized controlled trial: the WHEL study. The results of this study, and the two previous in 2009, should give practitioners and women alike great reassurance as to the safety of soy consumption for women with who have/have had a diagnosis of breast cancer. We no longer need to advise against soy consumption for breast cancer survivors. This is great news, given all the potential health benefits of soy for bone health and cardiovascular health, and as a part of a whole-food and healthful diet.
Caan B, Natarajan L, Parker B, et al. Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prey. 2011;20(5):854-858.
Red Wine As an Aromatase Inhibitor: Would It Be a Good Idea?
For this pilot study, premenopausal women with regular ovulatory cycles for 12 months with a body mass index between 18.5 and 30, no alcohol abuse, and normal serum liver function tests were recruited. Participants were randomly assigned to either red wine or white wine during the first study cycle and the other wine for the second cycle, consuming 8 ounces of the wine daily for 3 weeks. These 36 women were instructed not to drink any other alcohol or grape products during the research period. Blood was collected in the early follicular phase and the midluteal phase at baseline and during each wine phase, with a washout period in between.
Red wine consumption was associated with a significantly higher free testosterone and lower sex hormone binding globulin (SHBG) compared with white wine consumption. A nonstatistically significant trend toward lower levels was seen in total estradiol levels with the red wine compared with white wine. There was also a nonstatistically significant higher FSH level with red wine while LH was significantly different. According to the authors, these results of a higher free testosterone, lower SHBG, and higher LH suggest an aromatase-inhibiting effect of red wine.
Aromatase inhibitor (Al) drugs are used mainly to manage estrogen--receptor positive breast cancers in postmenopausal women. Als work by preventing the conversion of androstenedione and testosterone into estrogen and, by doing so, lead to increases in serum testosterone and decreases in estradiol, estrone, and SHBG. Als are found not only in red wine, but in grapes, grape juice, grape-seed extract, and some mushrooms. White wine apparently does not contain Als.
The benefit/risk balance of alcohol for women is complicated. Yes, there can be benefits in up to a certain amount of alcohol consumption, particularly cardiovascular. However, the amount to gain optimal benefit may exceed the amount that does harm, particularly in the realm of cancers of the larynx, oral cavity, pharynx, and esophagus. Statistically significant increases in risk also exist for cancers of the breast, stomach, colon, rectum, liver, and ovaries.
In summary, it appears that the majority of epidemiologic studies do provide scientific evidence for a positive association between breast cancer risk and alcohol consumption. Less than 1 drink per day is unlikely to significantly affect breast cancer risk--unless you are have or have had breast cancer, in which case less than 3 drinks per week may be the threshold to not increase your risk of recurrence, according to a recent study. Regular alcohol at 1 or 2 drinks per day may contribute to a modest increase in breast cancer risk. My view is that we know many ways to reduce our risk of cardiovascular disease, but few ways to lower our risk of breast cancer. Alcohol intake is one of those lifestyle factors that we can modify in order to reduce our risk.
Shufelt C, Merz CN, Yang Y, et al. Red versus white wine as a nutritional aromatase inhibitor in premenopausal women. j Women's Health. Epub 2011;doi:10.1089/jwh.2011.3001.
by Tod Hudson, ND
Dr. Tori Hudson graduated from the National College of Naturopathic Medicine (NCNM) in 1984 and has served the college in many capacities over the last 25 years. She is currently a clinical professor at NCNM and Bastyr University; has been in practice for over 28 years; and is the medical director of the clinic A Woman's Time in Portland, OR,
and director of research and development for Vitanica, a supplement company for women. She is also a nationally recognized author, speaker, educator, researcher, and clinician.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|